Fundraising FoxVersantis
Acquired5 known investors
Find your way into Versantis
GENFIT is a biopharmaceutical company developing therapies for rare, life-threatening liver diseases, with a focus on acute-on-chronic liver failure (ACLF), hepatic encephalopathy (HE), cholangiocarcinoma, urea cycle disorders, and organic acidemias. Its pipeline spans eight R&D programs plus a diagnostic franchise for NASH/MASH and ammonia, and it discovered elafibranor, now approved and marketed as Iqirvo for primary biliary cholangitis.
Investors · 5
.jpeg){kind=logo}
Esperante VenturesreportedLondon · $540K – $5.4M
How we know: press coverage · Not right? Tell us
HealthequityreportedBarcelona
How we know: funding news · press coverage · Not right? Tell us
redalpinereportedZug · $108K – $2.2M
How we know: press coverage · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AMar 2017Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Frequently asked questions
- What does Versantis do?
- GENFIT is a biopharmaceutical company developing therapies for rare, life-threatening liver diseases, with a focus on acute-on-chronic liver failure (ACLF), hepatic encephalopathy (HE), cholangiocarcinoma, urea cycle disorders, and organic acidemias. Its pipeline spans eight R&D programs plus a diagnostic franchise for NASH/MASH and ammonia, and it discovered elafibranor, now approved and marketed as Iqirvo for primary biliary cholangitis.
- Who are Versantis's investors?
- Versantis's investors include OCCIDENT, Verve Ventures, Esperante Ventures, Healthequity, redalpine.